Jefferies analyst Eun Yang views last week's 20% rise in La Jolla Pharmaceutical shares as "surprising" since key findings from the detailed Phase 3 data are in-line with prior top-line data. The analyst continues to view FDA approvability for LJPC-501 as high, but feels the commercial potential "could be debatable." Despite the reduction in catecholamine use with LJPC-501, there does not appear difference in cardiac disorders/safety between the LJPC-50 and placebo groups, Yang tells investors in a research note. The analyst keeps a Buy rating on La Jolla with a $40 price target.